NCT06710470View on ClinicalTrials.gov

A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring

Active, not recruitingOBSERVATIONAL
Enrollment

833

Participants

Timeline

Start Date

August 2, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

February 28, 2029

Conditions
Psoriasis
Interventions
DRUG

Deucravacitinib

As per product label

DRUG

Systemic psoriasis medications

As per product label

OTHER

No systemic medications

Participants not exposed to any systemic medications

Trial Locations (1)

08648

Bristol-Meyers Squibb, Lawrenceville

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06710470 - A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their Offspring | Biotech Hunter | Biotech Hunter